Shanghai-based asset manager focused on active equity and fixed-income strategies for institutional and high-net-worth clients across China and Greater China markets. GF Fund Management Co. Ltd. is known for proprietary research-driven portfolio construction, multi-asset fund offerings and segregated mandate capabilities, with emphasis on domestic A-shares, bonds and fund-of-funds solutions. Positioned as a domestic full-service manager, it competes on distribution, product innovation and onshore regulatory compliance.
Shanghai-based asset manager focused on active equity and fixed-income strategies for institutional and high-net-worth clients across China and Greater China markets. GF Fund Management Co. Ltd. is known for proprietary research-driven portfolio construction, multi-asset fund offerings and segregated mandate capabilities, with emphasis on domestic A-shares, bonds and fund-of-funds solutions. Positioned as a domestic full-service manager, it competes on distribution, product innovation and onshore regulatory compliance.
Research-led, onshore multi-asset manager prioritizing active equity and fixed-income allocations across China and Greater China markets. Portfolios are constructed from bottom-up proprietary research integrated with macro and policy analysis, favoring high-conviction A-share positions, credit selection in domestic bond markets, and fund-of-funds sleeves for diversification. Capital is deployed through segregated mandates and retail products with a bias toward medium-to-long horizons, disciplined risk controls, scenario stress testing, and distribution-led product innovation to align solutions with institutional and high-net-worth client objectives.
Research-led, onshore multi-asset manager prioritizing active equity and fixed-income allocations across China and Greater China markets. Portfolios are constructed from bottom-up proprietary research integrated with macro and policy analysis, favoring high-conviction A-share positions, credit selection in domestic bond markets, and fund-of-funds sleeves for diversification. Capital is deployed through segregated mandates and retail products with a bias toward medium-to-long horizons, disciplined risk controls, scenario stress testing, and distribution-led product innovation to align solutions with institutional and high-net-worth client objectives.
| Trades 4006 | Longs Won 2206/4006 55% | Profit Factor 4.29 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $8.73M |
| Average Win $1.43M | Best Trade (Oct 15) $330.18M | Sharpe Ratio -141.41 |
| Average Loss -$409,344.74 | Worst Trade (Oct 15) -$114.56M | Z-Score 4.6 (100%) |
| Commissions $0 | Avg. Trade Length 12m 4d | Expectancy $604,861.93 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 18,182 | 16,364 | 14,545 | 12,727 | 10,909 | 9,091 | 7,273 | 5,455 | 3,636 | 1,818 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 8176 81761L201 | 8,031 | $13,572 | $13,572 | - | - | - | 0.0 |
A Agilent Technologies Inc. | 7,785 | $1.04M | $1.34M | - | $304,776.05 | 29.3% | -1.595% |
AAPL Apple Inc. | 1.42M | $356.43M | $488.8M | - | $132.38M | 37.14% | +0.374% |
AARD Aardvark Therapeutics, Inc. | 452 | $5,408.28 | $1,760.86 | - | -$3,647.42 | -67.44% | +0.925% |
AAT American Assets Trust, Inc. | 665 | $17,242.91 | $14,114.62 | - | -$3,128.29 | -18.14% | -1.049% |
ABBV AbbVie Inc. | 48,257 | $8.92M | $13.76M | - | $4.84M | 54.28% | +0.632% |
ABCL AbCellera Biologics Inc. | 6,414 | $18,296.16 | $76,166.25 | - | $57,870.09 | 316.3% | -6.349% |
ABNB Airbnb, Inc. | 84,401 | $10.67M | $14.52M | - | $3.85M | 36.09% | -1.305% |
ABSI Absci Corporation | 3,184 | $8,554.15 | $26,283.92 | - | $17,729.77 | 207.27% | -7.038% |
ABT Abbott Laboratories | 47,558 | $5.6M | $4.96M | - | -$637,603.23 | -11.38% | -0.277% |
ABUS Arbutus Biopharma Corporation | 4,071 | $14,145.98 | $17,179.62 | - | $3,033.64 | 21.45% | -1.632% |
ABVX Abivax SA ADR | 1,302 | $171,655.92 | $114,191.91 | - | -$57,464.01 | -33.48% | -5.061% |
ACAD Acadia Pharmaceuticals Inc. | 3,609 | $66,749.73 | $69,401.07 | - | $2,651.34 | 3.97% | -2.435% |
ACIU Acimmune SA | 2,084 | $5,327.52 | $5,040.15 | - | -$287.37 | -5.39% | -1.286% |
ACN Accenture plc Class A | 947 | $234,258.16 | $212,904.54 | - | -$21,353.62 | -9.12% | -0.044% |
ACRS Aclaris Therapeutics, Inc. | 2,553 | $8,168.9 | $8,475.96 | - | $307.06 | 3.76% | -4.871% |
ADBE Adobe Inc. | 81,831 | $34.27M | $20.06M | - | -$14.21M | -41.47% | -2.611% |
ADC Agree Realty Corporation | 1,617 | $114,817.93 | $107,878.15 | - | -$6,939.78 | -6.04% | +0.233% |
ADEA Adeia Inc. | 15,460 | $509,098 | $321,954.5 | - | -$187,143.5 | -36.76% | -4.209% |
ADI Analog Devices, Inc. | 98,367 | $21.22M | $39.72M | - | $18.5M | 87.2% | -0.045% |